Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms

He, Fan; Laranjeira, Angelo B.A.; Kong, Tim; Lin, Shuyang; Ashworth, Katrina J.; Liu, Alice; Lasky, Nina M.; Fisher, Daniel A.C.; Cox, Maggie J.; Fulbright, Mary C.; Antunes-Heck, Lilian; Yu, LaYow; Brakhane, Molly; Gao, Bei; Sykes, Stephen M.; D’Alessandro, Angelo; Di Paola, Jorge; Oh, Stephen T.

doi:10.1172/jci172256

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article4

Book1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A sequential stimuli-responsive hydrogel promotes structural and functional recovery of severe spinal cord injury

Chen,

Wang,

Yang

et al. 2025

Biomaterials

View full text Add to dashboard Cite

A sequential stimuli-responsive hydrogel promotes structural and functional recovery of severe spinal cord injury

Chen,

Wang,

Yang

et al. 2025

Biomaterials

View full text Add to dashboard Cite

Aging-related alterations in mechanistic target of rapamycin signaling promote platelet hyperreactivity and thrombosis

Portier,

Manne,

Kosaka

et al. 2024

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Reduced Platelet Activation in Triple-Negative Essential Thrombocythemia Compared with JAK2V617F-Mutated Essential Thrombocythemia

Dong,

Chen,

Zhang

et al. 2024

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Triple-negative (TN) essential thrombocytopenia (ET) is characterized by the absence of driver mutations while retaining histological and phenotypic characteristics sufficient for an ET diagnosis. Our understanding of TN-ET and its platelet activation remains incomplete. We carried out a large-scale multi-center clinical analysis to analyze the clinical and molecular characteristics, thrombotic complications of TN-ET. We also related the above characteristics to platelet activation to further explore the thrombosis mechanism of TN-ET. Experimental Design:A retrospective multicenter study was conducted on 138 TN-ET and 759 ET patients with driver mutations from 1 March 2012 to 1 December 2021. The clinical and molecular characteristics of the TN-ET were summarized. Additionally, platelet activation, apoptosis, and reactive oxygen species (ROS) levels were analyzed in 73 TN-ET patients from this cohort and compared to 41 age- and sex-matched healthy donors.Results:Compared to patients with the JAK2V617F mutation, those with triple-negative mutation were younger (P < 0.001) and exhibited fewer thrombotic events before diagnosis (P < 0.001) and during follow-up (P = 0.039). Patients with triple-negative mutation also presented with significantly reduced CD62P expression in platelets (P = 0.031), slightly reduced calcium concentration in platelets (P = 0.063), increased mitochondrial membrane potential (P = 0.011), reduced phosphatidylserine exposure (P = 0.015), reduced levels of ROS (P = 0.043) and MitoSOX in platelets (P = 0.047).Conclusions: In comparison to JAK2V617F-mutated ET, TN-ET is associated with lower platelet ROS levels, which leads to reduced platelet activation and consequently a lower risk of thrombosis.

show abstract

Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms

Cited by 5 publications

References 62 publications

A sequential stimuli-responsive hydrogel promotes structural and functional recovery of severe spinal cord injury

A sequential stimuli-responsive hydrogel promotes structural and functional recovery of severe spinal cord injury

Aging-related alterations in mechanistic target of rapamycin signaling promote platelet hyperreactivity and thrombosis

Reduced Platelet Activation in Triple-Negative Essential Thrombocythemia Compared with JAK2V617F-Mutated Essential Thrombocythemia

Contact Info

Product

Resources

About